Fernanda Faiao-Flores
Overview
Explore the profile of Fernanda Faiao-Flores including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sriramareddy S, Faiao-Flores F, Emmons M, Saha B, Chellappan S, Wyatt C, et al.
Cancer Gene Ther
. 2022 Mar;
29(12):1840-1846.
PMID: 35332245
We previously demonstrated that pan-HDAC inhibitors could limit escape from MEK inhibitor (MEKi) therapy in uveal melanoma (UM) through suppression of AKT and YAP/TAZ signaling. Here, we focused on the...
2.
Udo M, da Silva M, de Souza Prates S, DalJovem L, Duro S, Faiao-Flores F, et al.
Arch Toxicol
. 2021 Mar;
95(5):1779-1791.
PMID: 33674969
Crack cocaine users are simultaneously exposed to volatilized cocaine and to its main pyrolysis product, anhydroecgonine methyl ester (AEME). Although the neurotoxic effects of cocaine have been extensively studied, little...
3.
Sandri S, Watanabe L, Oliveira E, Faiao-Flores F, Migliorini S, Tiago M, et al.
Pharmacol Res
. 2020 Jun;
159:104998.
PMID: 32535222
Indoleamine 2,3-dioxygenase (IDO) is associated with the progression of many types of tumors, including melanoma. However, there is limited information about IDO modulation on tumor cell itself and the effect...
4.
Alves-Fernandes D, Oliveira E, Hastreiter A, Faiao-Flores F, Felipe-Silva A, Turato W, et al.
Food Chem Toxicol
. 2020 Apr;
141:111371.
PMID: 32334110
NRAS-mutations arise in 15-20% of all melanomas and are associated with aggressive disease and poor prognosis. Besides, the treatment for NRAS-mutant melanoma are not very efficient and is currently limited...
5.
de Souza N, Oliveira E, Faiao-Flores F, Pimenta L, Quincoces J, Sampaio S, et al.
Anticancer Agents Med Chem
. 2020 Feb;
20(9):1038-1050.
PMID: 32067622
Background: Melanoma is the most aggressive skin cancer, and BRAF (V600E) is the most frequent mutation that led to the development of BRAF inhibitors (BRAFi). However, patients treated with BRAFi...
6.
Faiao-Flores F, Smalley K
Melanoma Manag
. 2019 Dec;
6(4):MMT29.
PMID: 31871618
No abstract available.
7.
Goncalves J, Emmons M, Faiao-Flores F, Aplin A, Harbour J, Licht J, et al.
Pigment Cell Melanoma Res
. 2019 Nov;
33(3):507-514.
PMID: 31758842
MEK inhibitors (MEKi) demonstrate anti-proliferative activity in patients with metastatic uveal melanoma, but responses are short-lived. In the present study, we evaluated the MEKi trametinib alone and in combination with...
8.
Faiao-Flores F, Emmons M, Durante M, Kinose F, Saha B, Fang B, et al.
Clin Cancer Res
. 2019 Jun;
25(18):5686-5701.
PMID: 31227503
Purpose: The clinical use of MEK inhibitors in uveal melanoma is limited by the rapid acquisition of resistance. This study has used multiomics approaches and drug screens to identify the...
9.
Emmons M, Faiao-Flores F, Sharma R, Thapa R, Messina J, Becker J, et al.
Cancer Res
. 2019 Apr;
79(11):2947-2961.
PMID: 30987999
Melanoma cells have the ability to switch to a dedifferentiated, invasive phenotype in response to multiple stimuli. Here, we show that exposure of melanomas to multiple stresses including BRAF-MEK inhibitor...
10.
Alves-Fernandes D, Oliveira E, Faiao-Flores F, Alicea-Rebecca G, Weeraratna A, Smalley K, et al.
Pharmacol Res
. 2018 Dec;
141:63-72.
PMID: 30550954
Melanoma accounts for only 4% of malignant neoplasms of the skin, but is considered the most serious because it is highly deadly. Mutations in the MAPK (Ras-Raf-MEK-ERK) pathway is closely...